The global non-small cell lung cancer market had a market value of US$ 10 billion in 2023 and is predicted to reach a market value of US$ 20 billion by 2033, growing at a CAGR of 7.2% from 2023 to 2033. Its rapid expansion can be attributed to an increasing patient population, the projected introduction of many treatments, and greater investment in NSCLC research and development by market participants.
Non-small cell lung cancer, one of the most common kinds of lung cancer, reduces the lungs’ ability to provide oxygen to the blood. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide. The causes are passive smoking, active smoking, consuming polluted water, and being exposed to air pollution. It can, however, be treated with a variety of medicines such as immunotherapy, targeted therapy, and others.
Request Sample Copy of Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16143
The two primary causes of non-small cell lung cancer are excessive tobacco intake and active participation in passive smoking. Long-term air pollution exposure promotes the development of non-small cell lung cancer. However, the existence of large firms, as well as the entry of new essential players, will result in excessive market rivalry. This will decrease the rate of expansion of the lung cancer treatments market. The high expense of therapy or treatment will limit the scope of expansion even further. Because of the prevalence of advanced healthcare infrastructure, greater research and development capabilities by pharmaceutical firms, and quick adoption of new and better healthcare technology, North America leads the non-small cell lung cancer market. Asia-Pacific, on the other hand, is expected to have the greatest growth rate throughout the projection period due to increased healthcare infrastructure spending, increasing prevalence of non-small cell lung cancer, and a growing senior population sensitive to cancer.
Key Takeaways from the Market Study
- FMI projects the global non-small cell lung cancer market to expand at a 7.2% value CAGR by 2033
- The global non-small cell lung cancer market is estimated at a market value of US$ 10 Billion
- The global non-small cell lung cancer market is expected to garner a market value of US$ 20 Billion
- North America is forecast to be the most lucrative for non-small cell lung cancer market growth.
- As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.7% during the assessment period 2023-2033.
- Europe is expected to grow at a CAGR of 7% during the assessment period 2023 to 2033.
- The chemotherapy segment is expected to hold the largest market share for non-small cell lung cancer in the forecast period 2023 to 2033.
Ask an Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-16143
“Rising investment in research & development efforts by the key players will fuel market expansion even more,” says an analyst at FMI
Market Competition
Key players in the non-small cell lung cancer market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Sanofi, Astellas Pharma Inc.
Recent Developments:
- In December 2022, Pluvicto®, a targeted radioligand treatment, has been authorised by the European Commission (EC), according to Novartis. Pluvicto® is licensed for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition (mCRPC). AR pathway inhibitor and taxane-based chemotherapy were used to treat these individuals.
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the global non-small cell lung cancer market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Buy Complete Report @
https://www.futuremarketinsights.com/checkout/16143
Key Segments Profiled in the Non-Small Cell Lung Cancer Market Industry Survey
Non-Small Cell Lung Cancer Market by Cancer Type:
- Squamous Cell Carcinoma
- Adenocarcinoma
- Large-cell Carcinoma
Non-Small Cell Lung Cancer Market by Treatment:
- Chemotherapy
- Targeted Therapy
- Immunotherapy
About the Healthcare at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
